Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Molecular Diagnostics' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Assessment of the Molecular Diagnostic Market for 44 NA Tests in UK |
April 2009 | £8065 | 100 % |
|
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Spain |
April 2009 | £8065 | 98 % |
|
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Italy |
April 2009 | £8065 | 98 % |
|
Assessment of the Molecular Diagnostic Market for 44 NA Tests in Germany |
April 2009 | £8065 | 98 % |
|
Assessment of the Molecular Diagnostic Market for 44 NA Tests in France |
April 2009 | £8065 | 98 % |
|
Assessment of the Molecular Diagnostic Market for Adenovirus NA Tests in Germany |
April 2009 | £360 | 97 % |
|
Molecular Diagnostics Major World Markets |
February 2007 | £2640 | 95 % |
|
Molecular Diagnostics A Dynamic and Rapidly Broadening Market Overview |
January 2009 | £2475 | 95 % |
|
Who's Doing What in Molecular Diagnostics? Kalorama / Emmes Survey of US Laboratories |
February 2002 | £3300 | 95 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
March 2010 | £3300 | 95 % |
|
Molecular Diagnostics in China |
February 2008 | £2640 | 94 % |
|
Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market |
July 2008 | £1715 | 94 % |
|
Molecular Diagnostics Markets |
September 2008 | £2245 | 94 % |
|
Molecular Diagnostics 2007 Technologies, Companies, Products, Applications and Worldwide Outlook |
May 2007 | £1515 | 94 % |
|
Global Molecular Diagnostics Market Opportunities & Future Forecast |
August 2009 | £660 | 93 % |
|
Molecular Diagnostics in Cancer Testing |
December 2009 | £2245 | 93 % |
|
World Market for Molecular Diagnostics, The |
January 2009 | £2640 | 93 % |
|
Molecular Diagnostics: a primer on an emerging sector |
November 2008 | £2640 | 92 % |
|
The Top 100 Molecular Diagnostics Manufacturing Companies Worldwide |
March 2009 | £625 | 92 % |
|
An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology |
May 2006 | £3140 | 91 % |
|
HIV Viral Load NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Viral Load NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Genotyping NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HLA Typing NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Viral Load NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HLA Typing NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Genotyping NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Genotyping NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HLA Typing NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HLA Typing NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HLA Typing NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Genotyping NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Adenovirus NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
BK Virus NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
BK Virus NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
BK Virus NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
BK Virus NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
BK Virus NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMF Viral Load NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMF Viral Load NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Adenovirus NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Adenovirus NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Qualitative NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Qualitative NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Viral Load NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Qualitative NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Qualitative NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Adenovirus NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Genotyping NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Viral Load NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Quantitative NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Human Metapneumovirus (hMPV) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Human Metapneumovirus (hMPV) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Influenca A/B NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Qualitative NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Human Metapneumovirus (hMPV) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Human Metapneumovirus (hMPV) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Her2Neu NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Her2Neu NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Human Metapneumovirus (hMPV) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Influenca A/B NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Influenca A/B NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Viral Load NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MAC NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MAC NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MAC NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MAC NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Qualitative NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Influenca A/B NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MAC NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Her2Neu NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Her2Neu NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Qualitative NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Viral Load NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Viral Load NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 1 NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMF Viral Load NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Quantitative NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Quantitative NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Quantitative NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 1 NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 1 NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 2 NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 2 NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Her2Neu NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 2 NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 2 NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 1 NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 1 NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HSV 2 NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HPV Quantitative NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMV Quant NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group B Streptococcus (GBS) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group A Streptococcus (GAS) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group A Streptococcus (GAS) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group A Streptococcus (GAS) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group B Streptococcus (GBS) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group B Streptococcus (GBS) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Quantitative NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group B Streptococcus (GBS) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group B Streptococcus (GBS) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group A Streptococcus (GAS) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Group A Streptococcus (GAS) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor V Leiden NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor V Leiden NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor V Leiden NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor V Leiden NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Fragile X NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Fragile X NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Fragile X NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Fragile X NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Fragile X NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Quantitative NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Quantitative NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Genotyping NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Genotyping NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Viral Load NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Viral Load NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Genotyping NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Genotyping NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Qualitative NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Qualitative NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Genotyping NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Viral Load NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Viral Load NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Ressistance NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Quantitative NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Quantitative NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Ressistance NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Ressistance NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Viral Load NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Ressistance NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HBV Ressistance NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor V Leiden NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor II NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia trachomatis/Neisseria gonorrheae (CT/NG) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia trachomatis/Neisseria gonorrheae (CT/NG) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia trachomatis/Neisseria gonorrheae (CT/NG) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia Trachomatis (CT) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia trachomatis/Neisseria gonorrheae (CT/NG) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia trachomatis/Neisseria gonorrheae (CT/NG) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Clostridium Difficile (C.diff) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Clostridium Difficile (C.diff) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Clostridium Difficile (C.diff) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia Trachomatis (CT) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia Trachomatis (CT) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Viral Load NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMV Quant NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMF Viral Load NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMV Quant NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMV Quant NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia Trachomatis (CT) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Chlamydia Trachomatis (CT) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMV Quant NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Clostridium Difficile (C.diff) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Clostridium Difficile (C.diff) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Epstein-Barr Virus (EBV) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Epstein-Barr Virus (EBV) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Epstein-Barr Virus (EBV) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Epstein-Barr Virus (EBV) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Epstein-Barr Virus (EBV) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor II NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor II NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor II NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Factor II NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Enterovirus NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Enterovirus NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Cystic Fibrosis, Mucoviscoidosis NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Cystic Fibrosis, Mucoviscoidosis NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Cystic Fibrosis, Mucoviscoidosis NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Cystic Fibrosis, Mucoviscoidosis NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Cystic Fibrosis, Mucoviscoidosis NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Enterovirus NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Enterovirus NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Enterovirus NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
CMF Viral Load NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Influenca A/B NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Neisseria Gonorrheae (NG) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Neisseria Gonorrheae (NG) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Neisseria Gonorrheae (NG) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Staphylococcus aureus NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Staphylococcus aureus NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Parainfluenza 1, 2, 3 NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Neisseria Gonorrheae (NG) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Neisseria Gonorrheae (NG) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium tuberculosis (MTB) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium tuberculosis (MTB) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VZV NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium tuberculosis (MTB) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Genotyping NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium tuberculosis (MTB) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MRSA NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Staphylococcus aureus NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Genotyping NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Genotyping NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
RSV NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
RSV NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VZV NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
RSV NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Genotyping NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
RSV NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Parainfluenza 1, 2, 3 NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
RSV NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VRE NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Genotyping NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Parainfluenza 1, 2, 3 NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Parainfluenza 1, 2, 3 NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Parainfluenza 1, 2, 3 NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Staphylococcus aureus NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VZV NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium tuberculosis (MTB) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MSSA NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VRE NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MSSA NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MRSA NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MRSA NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium Tuberculosis Direct (MTD) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MSSA NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MSSA NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MRSA NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VZV NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VRE NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HCV Viral Load NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium Tuberculosis Direct (MTD) NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VRE NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Staphylococcus aureus NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VZV NA Tests in UK Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
VRE NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MRSA NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
HIV Qualitative NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium Tuberculosis Direct (MTD) NA Tests in Germany Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium Tuberculosis Direct (MTD) NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Mycobacterium Tuberculosis Direct (MTD) NA Tests in Spain Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Warfarin sensitivity (CYP2C9, VKOR1) NA Tests in France Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
MSSA NA Tests in Italy Assessment of the Molecular Diagnostic Market |
April 2009 | £360 | 70 % |
|
Commercial Opportunities from Biomarkers Transforming drug discovery, clinical development and molecular diagnostic |
May 2006 | £1495 | 67.2 % |
|
China Molecular Diagnostics & Database Package |
January 2008 | £3300 | 35 % |
|
Gene Amplification Technologies Trends & Opportunities Worldwide |
November 2009 | £1980 | 35 % |
|
In Vitro Diagnostic Companies Analysis |
September 2007 | £595 | 32.5 % |
|
Who is Who in Clinical Diagnostics in China (Manufacturers and Distributors Profiles, Market, Industry Overview ) |
May 2009 | £2640 | 27.5 % |
|
Rapid Advances in HIV/AIDS Clinical Diagnostics |
June 2009 | £4295 | 27 % |
|
Leading Cancer Diagnostics Market Players Strategic Assessments of Major Suppliers and Emerging Market Entrants |
September 2009 | £1455 | 26.95 % |
|
Molecular Diagnostics A World Market Review |
November 2009 | £1980 | 26.25 % |
|
Nuclear Medicine A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 25 % |
|
Chinese Markets for In Vitro Diagnostics |
January 2010 | £2640 | 24.5 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £2970 | 24.5 % |
|
Xenomics, Inc. - Strategic Analysis Review |
July 2009 | £83 | 24 % |
|
How to React to Parallel Trade |
January 2007 | £1095 | 24 % |
|
DNA Probes-Based Diagnostics A Worldwide Market Review |
November 2009 | £1980 | 23.45 % |
|
Innovations in Diagnostics |
September 2006 | £1495 | 23.1 % |
|
Swine Influenza Market Alert (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) |
May 2009 | £530 | 22.4 % |
|
Diagnostic Imaging Market Profile |
November 1999 | £1735 | 22.4 % |
|
Third Wave Technologies, Inc. - SWOT Analysis |
September 2008 | £44 | 22 % |
|
Personalized Medicine |
August 2007 | £1320 | 21.7 % |
|
Diagnosis of Fungal Infections |
August 2007 | £115 | 21.35 % |
|
Diagnostics & Pathology in India |
April 2009 | £600 | 21.35 % |
|
Diagnosis of Fungal Infections |
December 2007 | £115 | 21.35 % |
|
Convergence of Biomarkers and Diagnostics, The Therapy Area Analyses, Key Products and Future Trends |
April 2008 | £1995 | 21 % |
|
Gastrointestinal Oncology Evidence and Analysis |
June 2007 | £115 | 20 % |
|
Qiagen N.V. - Financial and Strategic Analysis Review |
June 2009 | £83 | 20 % |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 | 19.95 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 19.5 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 19.5 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 19.5 % |
|
Nanobiotechnologies Applications, Markets and Companies |
May 2009 | £2640 | 19 % |
|
European Point of Care (POC) Infectious Disease Market |
December 2008 | £3965 | 18.5 % |
|
In Vitro Diagnostics in a Recession IVD Market Forecasts, Analysis and Success Strategies |
May 2009 | £1980 | 18.2 % |
|
Infectious Disease Diagnostic Markets |
August 2009 | £2310 | 18.2 % |
|
Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) |
June 2008 | £1980 | 18.2 % |
|
Myriad Genetics, Inc. - SWOT Analysis |
September 2008 | £44 | 18 % |
|
Partnering Agreements In Diagnostics Trends in diagnostics partnering deals |
September 2009 | £1195 | 17.85 % |
|
Myeloproliferative Disorders: Biology and Management |
October 2007 | £105 | 17.85 % |
|
Cardiovascular Disease Diagnostics A World Market Intelligence Report |
November 2009 | £1980 | 17.85 % |
|
U.S. DNA-Based Diagnostic Test and Equipment Market Analysis & Directions Market Trends, New Product Trends, Technology Trends, Distribution Structure and 15 Notable Company Case Studies |
September 2009 | £1850 | 17.15 % |
|
Multiple Myeloma |
October 2007 | £105 | 17.15 % |
|
Complete Guide to the Diagnostic Market 2007-2012 |
January 2007 | £1600 | 17.15 % |
|
Microfluidics : Point of Care Testing Applications of Microfluidics Technologies |
March 2010 | £3215 | 17 % |
|
2007 The Worldwide Biochip & Equipment Market |
August 2006 | £1185 | 17 % |
|
Medical Imaging Markets, Volume IV Contrast Agents |
February 2007 | £1980 | 17 % |
|
Clinica's Indian Market Briefing |
January 2006 | £500 | 16.8 % |
|
Genomic Health, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 16.5 % |
|
IRIS International, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 16.5 % |
|
Gene Express, Inc. Product Pipeline Analysis |
August 2008 | £495 | 16.1 % |
|
Cell-Based Diagnostics: Technology, Applications, and Markets 2nd Edition |
November 2007 | £2640 | 16.1 % |
|
Cytology and HPV Testing World Markets |
July 2008 | £2245 | 16.1 % |
|
BG Medicine, Inc. Product Pipeline Analysis |
August 2008 | £495 | 15.75 % |
|
Top Ten Global In-Vitro Diagnostics Companies Positioning, performance and SWOT analyses |
March 2009 | £2025 | 15.75 % |
|
Diagnostics & Pathology Laboratories |
April 2008 | £600 | 15.4 % |
|
Bacteriology Clinical Trial Analysis |
July 2009 | £660 | 15.4 % |
|
DNA Diagnostics: Technologies and Global Markets |
January 2008 | £3205 | 15.05 % |
|
Roche Diagnostics Limited Product Pipeline Analysis |
August 2008 | £495 | 15.05 % |
|
Stakeholder Opinions: Restless Legs Syndrome Novel drugs to prosper as lifecycle management strategies fail |
November 2008 | £2640 | 15.05 % |
|
Osmetech plc Product Pipeline Analysis |
August 2008 | £495 | 15.05 % |
|
Qiagen N.V. Product Pipeline Analysis |
August 2008 | £495 | 14.7 % |
|
Epigenetics Technologies, Applications, and the Commercial Landscape |
February 2008 | £1240 | 14.7 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2245 | 14.7 % |
|
Cancer Diagnostic Testing Instrumentation Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers |
September 2009 | £330 | 14.7 % |
|
Molecular Imaging in Drug R&D and Medical Practice Technologies, Applications, Markets |
January 2008 | £745 | 14.35 % |
|
SEQUENOM, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 14 % |
|
Gen-Probe Medical Equipment Company Share Analysis |
July 2008 | £335 | 13.65 % |
|
Biomarkers The Expanding Global Market |
November 2007 | £3205 | 13.3 % |
|
Multiplex Assays Evolving Technologies, Applications and Future Directions |
December 2009 | £2475 | 13.3 % |
|
Blood Banking Technologies Assessment of Current and Emerging Technologies, and Their Potential Market Applications |
September 2009 | £890 | 13.3 % |
|
U.S.DNA-Based Diagnostic and Test Market |
January 2008 | £1850 | 13.3 % |
|
Therapeutic Drug Market for Acne Sector Snapshot |
May 2006 | £330 | 13.3 % |
|
Biologic Imaging Reagents Technologies and Global Markets |
December 2008 | £3205 | 13.3 % |
|
Outlook 2007 |
January 2006 | £895 | 13 % |
|
Biomarker Technology Platforms for Cancer Diagnoses and Therapies |
April 2008 | £2245 | 12.95 % |
|
Biomarkers: A Market Briefing A Market Briefing |
January 2007 | £1320 | 12.95 % |
|
Cancer Diagnostic Testing World Markets |
April 2008 | £2245 | 12.95 % |
|
Disease Specific Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 12.95 % |
|
Cell Culture The World Market for Media, Sera, and Reagents |
January 2007 | £2575 | 12.95 % |
|
Medical Weekly Deals Summaries 24 August 2009 |
August 2009 | £83 | 12.95 % |
|
Diagnostic Medical Imaging Equipment Market Outlook Emerging Developments, Opportunities and Worldwide Market |
November 2007 | £1515 | 12.95 % |
|
Lateral Flow Technology and the Future of Point of Care Diagnostics |
February 2007 | £1980 | 12.6 % |
|
Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
July 2008 | £1320 | 12.6 % |
|
Medical Membrane Devices Markets and Technologies |
July 2009 | £3205 | 12.6 % |
|
Radiopharmaceuticals A US and European Market Analysis |
November 2009 | £1980 | 12.6 % |
|
Nanogen, Inc. - Financial and Strategic Analysis Review |
April 2009 | £83 | 12.5 % |
|
Personalized Medicine: Technologies and the Global Market |
July 2009 | £3205 | 12.5 % |
|
Gen-Probe Incorporated Healthcare - Medical Equipment SWOT Report |
August 2008 | £83 | 12.25 % |
|
Clinical Laboratory Testing Volume 1: Reagents and Instruments |
April 2009 | £2245 | 12.25 % |
|
Cepheid Product Pipeline Analysis |
August 2008 | £495 | 12.25 % |
|
The French Cancer Diagnostics Market |
September 2009 | £2710 | 12.25 % |
|
Cancer Diagnostic Technologies Assessment of Current and Emerging Technologies, and Their Potential Market Applications |
September 2009 | £1125 | 12.25 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £745 | 12 % |
|
Medical Nanotechnology Markets |
September 2008 | £2245 | 12 % |
|
Immunoassay Instruments Global Market Trends |
November 2009 | £1980 | 11.9 % |
|
The Japanese Cancer Diagnostics Market |
September 2009 | £3765 | 11.9 % |
|
The Italian Cancer Diagnostics Market |
September 2009 | £2710 | 11.9 % |
|
The Spanish Cancer Diagnostics Market |
September 2009 | £2710 | 11.9 % |
|
Cardiovascular Biomarkers: Players, products and prospects (Volume III) |
August 2008 | £595 | 11.9 % |
|
Siemens Medical Solutions Healthcare - Medical Equipment SWOT Report |
August 2008 | £83 | 11.9 % |
|
Gamma Camera Clinical Trial Analysis |
July 2009 | £660 | 11.9 % |
|
Clinical Laboratory Testing Volume 2: Business Strategies |
April 2009 | £1320 | 11.9 % |
|
The US Cancer Diagnostics Market |
September 2009 | £4885 | 11.9 % |
|
The UK Cancer Diagnostics Market |
September 2009 | £2710 | 11.9 % |
|
Genomics World Markets |
May 2008 | £2245 | 11.9 % |
|
The German Cancer Diagnostics Market |
September 2009 | £2710 | 11.55 % |
|
Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
December 2008 | £2475 | 11.55 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £660 | 11.55 % |
|
Impact of Pharmacogenomics on Public Healthcare Policy Educating Patients, Payors and Healthcare Providers |
March 2008 | £1995 | 11.55 % |
|
Medical Equipment M&A Trends November 2008 |
November 2008 | £660 | 11.55 % |
|
Systemic Fungal Infection Therapeutics Research - Malaysia |
October 2009 | £3965 | 11.5 % |
|
Systemic Fungal Infection Therapeutics Market- Taiwan |
November 2009 | £3965 | 11.5 % |
|
Systemic Fungal Infection Therapeutics Market - Singapore |
November 2009 | £3965 | 11.5 % |
|
Systemic Fungal Infection Therapeutics Market - India |
November 2009 | £3965 | 11.5 % |
|
Imaging Agents A Worldwide Market Review |
November 2009 | £1980 | 11.2 % |
|
Third Wave Technologies, Inc. Product Pipeline Analysis |
August 2008 | £495 | 11.2 % |
|
Global Tuberculosis Strategies |
June 2007 | £2640 | 11.2 % |
|
BioChips & BioMEMS (Bio Microelectromechanical Systems) World Markets, Applications & Opportunities 2006-2011 Analysis & Forecasts |
May 2006 | £1185 | 11 % |
|
RNA Interference Markets |
December 2008 | £2245 | 11 % |
|
Systemic Fungal Infection Therapeutics Market - South Korea |
October 2009 | £3965 | 11 % |
|
Systemic Fungal Infection Therapeutics Market - Australia |
November 2009 | £3965 | 11 % |
|
Cholesterol and Other Cardiovascular Testing Trends & Opportunities Worldwide |
November 2009 | £1980 | 10.85 % |
|
DNA Sequencing and PCR Markets |
July 2008 | £2245 | 10.85 % |
|
Siemens Medical Solutions Medical Device Company Intelligence Report |
February 2007 | £395 | 10.85 % |
|
Automated and Rapid Microbiological Tests A Worldwide Market Review |
November 2009 | £1980 | 10.85 % |
|
Altana AG Deals Partneringdesk briefing |
July 2005 | £215 | 10.5 % |
|
Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
July 2009 | £945 | 10.5 % |
|
Nanotechnology Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics |
January 2008 | £1995 | 10.5 % |
|
Siemens Healthcare Medical Device Company Intelligence Report |
August 2009 | £295 | 10.5 % |
|
The US Blood Banking Market through 2013 |
September 2009 | £4490 | 10.5 % |
|
Drug Related Testing Reagents Clinical Trial Analysis |
July 2009 | £660 | 10.5 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3205 | 10.5 % |
|
Cardiac Biomarkers A Global Market Perspective |
November 2009 | £1980 | 10.5 % |
|
United Kingdom in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1650 | 10.5 % |
|
Emerging Opportunities in Cancer Nanomedicine |
August 2006 | £995 | 10.5 % |
|
Medical Diagnostic Kits |
January 2008 | £3205 | 10.5 % |
|
Disease Specific Markers Clinical Trial Analysis |
July 2009 | £660 | 10.15 % |
|
Global Medical Markets for Nanoscale Materials and Devices |
January 2008 | £3205 | 10.15 % |
|
Breast Cancer Drug Discoveries What the future holds |
December 2008 | £795 | 10.15 % |
|
Gen-Probe Incorporated Product Pipeline Analysis |
August 2008 | £495 | 10.15 % |
|
Infectious Immunology Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 10.15 % |
|
Exiqon AS Product Pipeline Analysis |
May 2008 | £495 | 10.15 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 10.15 % |
|
LifescienceIC Analysis of the applications and added value of semiconductor devices in life sciences |
May 2006 | £2230 | 10 % |
|
Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
June 2007 | £1495 | 10 % |
|
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions |
February 2008 | £745 | 9.8 % |
|
Understanding Pharmacogenomics Maximum Efficacy with Minimal Adverse Effects |
January 2009 | £395 | 9.8 % |
|
Medical Weekly Deals Summaries 01 June 2009 |
June 2009 | £83 | 9.8 % |
|
Hiv/Aids Testing World Review |
November 2009 | £1980 | 9.8 % |
|
Protein Therapeutics Market; The The Science and Business of a Growing Sector |
June 2006 | £2575 | 9.8 % |
|
Clinical Data, Inc. - Financial and Strategic Analysis Review |
April 2009 | £83 | 9.5 % |
|
Illumina, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 9.5 % |
|
Siemens Medical Solutions Product Pipeline Analysis |
August 2008 | £495 | 9.45 % |
|
The Worldwide Market for In Vitro Diagnostic Tests 6th Edition [with 2009 Economy Preface] |
May 2008 | £2640 | 9.45 % |
|
Roche Holding Ltd - Strategic Analysis Review |
March 2009 | £83 | 9.45 % |
|
In Vitro Diagnostics Market Analysis 2009-2024 |
May 2009 | £1499 | 9.45 % |
|
IT Software Tools for Life Science and Drug Discovery Bioscience, Biotechnology, Pharmaceutical Company and Institute's IT Software Tools, Strategy, and WW Market Outlook |
June 2009 | £1515 | 9.45 % |
|
Animal Biotechnology Technologies, Markets and Companies |
March 2010 | £1650 | 9.45 % |
|
Advances in Molecular Imaging Companies and Technologies that are driving change |
February 2010 | £695 | 9.1 % |
|
The Spanish Blood Banking Market through 2013 |
September 2009 | £2710 | 9.1 % |
|
The German Blood Banking Market through 2013 |
September 2009 | £2710 | 9.1 % |
|
Cytogenetics Technologies, Markets and Companies |
March 2010 | £1455 | 9.1 % |
|
Virology Clinical Trial Analysis |
July 2009 | £660 | 9.1 % |
|
The Italian Blood Banking Market through 2013 |
September 2009 | £2710 | 9.1 % |
|
The French Blood Banking Market through 2013 |
September 2009 | £2710 | 9.1 % |
|
The Japanese Blood Banking Market through 2013 |
September 2009 | £3630 | 9.1 % |
|
The UK Blood Banking Market through 2013 |
September 2009 | £2710 | 9.1 % |
|
Warnex Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 9 % |
|
Alseres Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 9 % |
|
Cepheid - Financial and Strategic Analysis Review |
June 2009 | £83 | 9 % |
|
Exact Sciences Corporation - Financial and Strategic Analysis Review |
June 2009 | £83 | 9 % |
|
Genetic Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 8.75 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 8.75 % |
|
Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players) |
April 2004 | £2310 | 8.75 % |
|
Mammography Equipment Clinical Trial Analysis |
July 2009 | £660 | 8.75 % |
|
Epigenomics AG - Financial and Strategic Analysis Review |
June 2009 | £83 | 8.75 % |
|
Advanced Digital Diagnostic Medical Imaging Equipment Market Analysis & Directions |
September 2009 | £1515 | 8.75 % |
|
Biotechnology Reagents A Global Market Perspective |
November 2009 | £1980 | 8.75 % |
|
Genetic Testing A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 8.75 % |
|
Gene Expression Reagents Markets |
April 2007 | £1320 | 8.75 % |
|
Executive Summary of the BioChips & BioMEMS (Biomedical Microelectromechanical Systems) Markets 2006-2011 Analysis & Forecasts |
May 2006 | £725 | 8.5 % |
|
Understanding Genomics and Global Health Impacts The Study of Disease at the Cellular and Molecular Level |
January 2009 | £460 | 8.4 % |
|
Glycominds Ltd. Product Pipeline Analysis |
August 2008 | £495 | 8.4 % |
|
Biomarkers in Drug Discovery Optimizing Drug Discovery Timeline and Costs |
February 2010 | £2310 | 8.4 % |
|
Biomarkers: The Future of Next-Generation Drug R&D |
September 2008 | £1715 | 8.4 % |
|
Myriad Genetics, Inc. - Financial and Strategic Analysis Review |
April 2009 | £83 | 8.05 % |
|
Nanotechnology in Life Science Applications |
October 2005 | £2885 | 8.05 % |
|
Blood The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products |
September 2006 | £2575 | 8.05 % |
|
Innovative Drug R&D in China |
October 2009 | £1910 | 8.05 % |
|
Competitor Analysis: PSMA & PSA Targeted Therapy |
January 2010 | £135 | 8 % |
|
Canada In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012 |
September 2008 | £1980 | 7.7 % |
|
Patient Monitoring Markets |
October 2009 | £2245 | 7.7 % |
|
Enzymes US industry forecasts to 2010 & 2015 |
July 2006 | £2840 | 7.7 % |
|
Bioarrays for Life Science Research, Diagnostics and Drug R&D |
August 2009 | £1650 | 7.7 % |
|
Germany in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1650 | 7.7 % |
|
GPCRs: Dawn of a New Era? |
October 2008 | £2475 | 7.5 % |
|
Genzyme Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 7.5 % |
|
Burger's Medicinal Chemistry and Drug Discovery 6 Volume Set |
March 2003 | £1730 | 7.35 % |
|
Positron Emission Tomography Markets |
December 2007 | £1320 | 7.35 % |
|
Modern Biopharmaceuticals Design, Development and Optimization, 4 Volumes |
September 2005 | £440 | 7.35 % |
|
The 100 Biggest Acute Hospitals In Europe |
January 2009 | £625 | 7.35 % |
|
Pharmaceutical Regulatory Industry |
January 2006 | £2885 | 7.35 % |
|
Infectious Diseases Drugs Markets |
October 2009 | £2245 | 7.35 % |
|
Epigenetics |
February 2010 | £2970 | 7.35 % |
|
United States in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1650 | 7.35 % |
|
IRIS International, Inc. Product Pipeline Analysis |
August 2008 | £495 | 7 % |
|
Biomarkers, Tests and Trends for Drug R&D |
February 2010 | £1450 | 7 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 7 % |
|
next-Generation Immunoassays A Market and Technical Analysis of Research Applications 2007 |
December 2007 | £2300 | 7 % |
|
Labeling and Linkage Agents for Immunoassays and Gene Probes |
April 2006 | £2885 | 7 % |
|
Instruments Clinical Trial Analysis |
July 2009 | £660 | 7 % |
|
Carestream Health, Inc. Kodak Health Group Product Pipeline Analysis |
August 2008 | £495 | 7 % |
|
Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles) |
November 2008 | £1650 | 7 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2640 | 7 % |
|
United States In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012 |
September 2008 | £1980 | 6.65 % |
|
Biosensors in Medical Diagnostics International Market Trends |
November 2009 | £1980 | 6.65 % |
|
Microplate Instrumentation & Supplies A Global Market Perspective |
November 2009 | £1980 | 6.65 % |
|
Point of Care Diagnostics: Players, Products & Future Market Prospects |
November 2009 | £995 | 6.3 % |
|
Eastman Kodak Medical Device Company Intelligence Report |
April 2009 | £295 | 6.3 % |
|
Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
August 2005 | £2885 | 6.3 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2245 | 6.3 % |
|
Nanobiotechnology |
February 2010 | £2940 | 5.95 % |
|
Computed Tomography (CT) Systems Market Worldwide 2009 |
April 2009 | £1650 | 5.95 % |
|
United States in Vitro Diagnostics Industry Report Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Clinical Chemistry, Immunochemistry, Infectious Immunology, Microbiology, Genetic and Blood Test Reagents, Insturments and Test Kits |
May 2008 | £1980 | 5.95 % |
|
Pharmaceutical Contract Manufacturing and Research |
May 2005 | £2885 | 5.95 % |
|
Nanomedicine |
July 2009 | £2610 | 5.95 % |
|
Medical Plastics US industry forecasts for 2012 & 2017 |
February 2009 | £3105 | 5.95 % |
|
GE Healthcare Medical Device Company Intelligence Report |
April 2009 | £495 | 5.95 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
April 2009 | £2245 | 5.6 % |
|
World Enzymes Study # 2229 |
September 2007 | £3565 | 5.6 % |
|
Nanomedicine 2006-2011 |
June 2006 | £1499 | 5.6 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 5.5 % |
|
Medical Imaging Devices A Global Market Overview |
September 2009 | £2970 | 5.25 % |
|
India: Pharmaceutical and biotechnology opportunities |
April 2006 | £840 | 5.25 % |
|
Varian Medical Device Company Intelligence Report |
February 2009 | £295 | 5 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 4.9 % |
|
The Future of Contract Research Outsourcing Market Forecasts to 2015, Geographical Landscape and Competitive Benchmarking |
December 2009 | £2310 | 4.9 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.9 % |
|
Alzheimer's disease |
March 2010 | £2115 | 4.9 % |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £5020 | 4.9 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 4.9 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 4.9 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.9 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 4.9 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 4.9 % |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £1450 | 4.55 % |
|
Bayer Schering Pharma AG: PharmaVitae Profile |
July 2009 | £3765 | 4.55 % |
|
Taq Wars; The Competitive Intelligence on How to Survive |
November 2005 | £2970 | 4.55 % |
|
Biotechnological Innovations In The Pharmaceutical Industry in Poland 2009 Development forecasts for biotechnology sector for 2009-2011 |
August 2009 | £1790 | 4.55 % |
|
DNA Sequencing Technologies, Markets and Companies |
March 2010 | £1190 | 4.55 % |
|
Computed Tomography Systems Clinical Trial Analysis |
July 2009 | £660 | 4.55 % |
|
United Kingdom Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1980 | 4.2 % |
|
Therapeutic/Diagnostic Devices for Neurological Disorders |
March 2007 | £3205 | 4.2 % |
|
Drug Discovery Technologies A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 4.2 % |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £1320 | 4.2 % |
|
DNA Sequencing: Emerging Technologies and Applications |
January 2008 | £3205 | 4.2 % |
|
Therapeutic Monoclonal Antibodies Report 2008-2023 |
July 2008 | £1499 | 3.85 % |
|
Medical Device Development Regulation and Law |
September 2009 | £160 | 3.85 % |
|
Stakeholder Opinions: Skin and soft tissue infections |
July 2009 | £2510 | 3.85 % |
|
RNAi Technologies, Markets and Companies |
March 2010 | £2310 | 3.85 % |
|
Germany Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1980 | 3.85 % |
|
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders |
December 2008 | £2475 | 3.85 % |
|
Contract Pharmaceutical Manufacturing, Research, and Packaging |
October 2009 | £3205 | 3.85 % |
|
Lung Cancer Therapeutics |
July 2009 | £2610 | 3.85 % |
|
GE Healthcare Product Pipeline Analysis |
May 2008 | £495 | 3.5 % |
|
Japan Healthcare IT Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1980 | 3.5 % |
|
Medical Plastics |
November 2006 | £2885 | 3.5 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £3965 | 3.5 % |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £3965 | 3.15 % |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £5745 | 3.15 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 3.15 % |
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
July 2007 | £1999 | 3.15 % |
|
Picture Archiving and Communications Systems (PACS) |
September 2008 | £1320 | 3.15 % |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £4290 | 3.15 % |
|
Bayer Schering Pharma Ag PharmaVitae Profile |
July 2008 | £1980 | 3.15 % |
|
Partneringreview 2006 – Industry Sector Volume 6 |
February 2006 | £1395 | 3 % |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1980 | 2.8 % |
|
Therapeutics for Memory and Cognition Disorders |
April 2009 | £3205 | 2.8 % |
|
Nanomaterials Markets by Type |
December 2005 | £2885 | 2.8 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 2.8 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £1320 | 2.45 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1650 | 2.45 % |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 | 2.45 % |
|
Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts 2009 to 2015 |
February 2009 | £2245 | 2.45 % |
|
DNA Sequencing Equipment and Services Markets |
June 2007 | £2640 | 2.1 % |
|
DNA Sequencing Equipment and Services Markets, 2nd Edition |
August 2009 | £2510 | 1.75 % |
